Search results
Results from the WOW.Com Content Network
A large-scale study in Buenos Aires from December 29, 2020, to May 15, 2021, with 663,602 participants aged 60 and older who received Spunik V, the Oxford–AstraZeneca vaccine, or the Sinopharm BIBP vaccine observed an overall efficacy of 98% (95% CI, 95 – 99%) against COVID-19-related deaths. The study noted that the three vaccines showed a ...
Moderna has launched a trial of a vaccine to tackle the Beta variant or lineage B.1.351. [460] On 17 February 2021, Pfizer announced neutralization activity was reduced by two-thirds for this variant, while stating that no claims about the efficacy of the vaccine in preventing illness for this variant could yet be made. [461]
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
Russia was quick to develop its two-dose Sputnik V vaccine last year and has also deployed a one-shot Sputnik Light vaccine, both of which have it says demonstrated high efficacy in trials, but ...
Vaccine Initial effectiveness by severity of COVID-19 Study location Refs Asymptomatic Symptomatic Hospitalization Death Oxford–AstraZeneca
On 11 August 2020, President Putin said in a meeting that the Sputnik V vaccine (registered as Gam-COVID-Vac) developed by the Gamaleya Research Institute of Epidemiology and Microbiology was the first vaccine against the coronavirus to be registered.
Recently, after researching effectiveness, the FDA removed its emergency use authorization for several manufacturers of KN95 masks. Powecom masks made it through the tests. Powecom masks made it ...
While the efficacy rates were lower than the Pfizer–BioNTech and Moderna vaccines, its single-dose regimen and normal refrigerator storage requirement (2 to 8 °C) could make it a favorable option for many countries. It has similar efficacy to the Janssen vaccine, another one-shot adenovirus vaccine found to be 66% effective in a global trial.